IPHA
Innate Pharma

1,520
Mkt Cap
$164.98M
Volume
51,981.00
52W High
$3.51
52W Low
$1.41
PE Ratio
-3.00
IPHA Fundamentals
Price
$1.82
Prev Close
$1.79
Open
$1.83
50D MA
$1.98
Beta
0.40
Avg. Volume
22,782.78
EPS (Annual)
-$0.6602
P/B
27.32
Rev/Employee
$75,431.50
Loading...
Loading...
Innate Pharma SA is a global, clinical-stage biotechnology company, which engages in developing immunotherapies for cancer patients. Its product pipeline includes Lacutamab, Monalizumab, Avdoralimab, and IPH62. The company was founded by Hervé Eloi Dominique Brailly, Eric Vivier, Marc Bonneville, Alessandro Moretta, Jean-Jacques Fournié, and François Romagné on September 23, 1999 and is headquartered in Marseille, France.
Sector:
Health Technology
Industry:
Pharmaceuticals Major
Employees:
181

Frequently Asked Questions

What is Market Cap of Innate Pharma - ADR?
What is the 52-week high for Innate Pharma - ADR?
What is the 52-week low for Innate Pharma - ADR?
What is Innate Pharma - ADR stock price today?
What was Innate Pharma - ADR stock price yesterday?
What is the PE ratio of Innate Pharma - ADR?
What is the Price-to-Book ratio of Innate Pharma - ADR?
What is the 50-day moving average of Innate Pharma - ADR?
How many employess does Innate Pharma - ADR has?

Latest IPHA News

View

Advertisement|Remove ads.

Advertisement|Remove ads.